ORIC Pharmaceuticals Gears Up for Investor Engagements This April
ORIC Pharmaceuticals Engages with Investors
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a prominent clinical stage oncology company renowned for its efforts in developing treatments that combat mechanisms of therapeutic resistance, is set to participate in several key investor conferences this month. These events represent a significant opportunity for ORIC to share insights regarding their innovative strategies and product developments in the oncology sector.
Key Conferences Scheduled
Needham's Annual Healthcare Conference
On April 7, 2025, ORIC Pharmaceuticals will present a detailed overview of their company at Needham's 24th Annual Healthcare Conference. This presentation is scheduled for 1:30 p.m. ET and is expected to highlight the company's vision, core objectives, and groundbreaking advancements in cancer therapy.
Stifel Virtual Targeted Oncology Forum
Following this, on April 9, 2025, at 2:00 p.m. ET, ORIC will participate in a fireside chat during the Stifel 2025 Virtual Targeted Oncology Forum. This engaging session aims to foster a dialogue about the latest developments in targeted oncology treatments and ORIC's contributions to the field.
Webcast Availability
For those unable to attend the live presentations, webcasts will be made available through the investor section on ORIC's official website. These recordings provide invaluable insights and will remain accessible for 90 days post-event, ensuring broader access to ORIC's strategic outlines and future plans.
About ORIC Pharmaceuticals
ORIC Pharmaceuticals is dedicated to enhancing patient outcomes by overcoming resistance in cancer therapies. Their portfolio showcases remarkable clinical stage product candidates, including ORIC-944, designed as an allosteric inhibitor targeting the polycomb repressive complex 2 (PRC2) through the EED subunit, particularly for prostate cancer. Additionally, ORIC-114 stands out as a brain-penetrant inhibitor that selectively targets both EGFR and HER2 exon 20 mutations, alongside atypical mutations in EGFR, demonstrating potential across various genetically defined cancers.
Innovation in Cancer Treatment
Beyond their notable candidates, ORIC Pharmaceuticals is actively developing precision medicines aimed at addressing fundamental resistance mechanisms commonly encountered in cancer treatment. Their commitment to research and innovation positions the company as a leader in the oncology market, dedicated to delivering effective solutions for patients grappling with challenging cancer forms.
Company Presence
The company holds offices in both South San Francisco and San Diego, California, which are pivotal locations for its operations and research initiatives. Through these hubs, ORIC continues to engage with the scientific and medical communities to enhance treatment options for patients.
Contact Information
For additional information, inquiries can be directed to Dominic Piscitelli, Chief Financial Officer of ORIC, at dominic.piscitelli@oricpharma.com or via info@oricpharma.com.
Frequently Asked Questions
What is ORIC Pharmaceuticals' primary focus?
ORIC Pharmaceuticals specializes in developing oncology treatments that address therapeutic resistance mechanisms.
When will ORIC present at the Needham's Healthcare Conference?
ORIC is scheduled to present on April 7, 2025, at 1:30 p.m. ET.
What is ORIC-944?
ORIC-944 is an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) being developed for prostate cancer treatment.
How can I access ORIC's conference webcasts?
Webcasts of the presentations can be found on the investor section of ORIC's website, available for 90 days after the events.
What locations does ORIC Pharmaceuticals operate from?
ORIC has offices located in South San Francisco and San Diego, California.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.